Bardoxolone-methyl-treated patients in the BEACON substudy had a clinically meaningful reduction in urine volume and sodium excretion at week @ relative to baseline ( p < @ ) , and a separate study revealed that decreased sodium excretion and urine output occurred in some patients with stage @ CKD but not those with stage @b CKD .